Compare Hims and Hers Health Inc (HIMS) vs Unilever plc (UL) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

Unilever (UL) trades at $62.18, down 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. Recent quarterly earnings missed expectations, but the company maintains strong profitability with a 46.95% gross margin and 18.75% net margin. Key developments include a pending food business divestiture to McCormick and a $270 million innovation center investment, signaling strategic focus on core brands and digital transformation.

The outlook is mixed: valuation appears fair with a P/E of 21.15, but earnings misses and competitive pressures pose risks. Analyst consensus is cautious with 51% hold ratings. Long-term opportunities lie in emerging market growth and cost efficiencies, though near-term execution and macroeconomic headwinds require monitoring.